Not surprisingly, in a more recent study, it was shown that a shift from ER-positve breast cancer to ER-negative CTCs in metastatic disease was associated with a worse prognosis as compared to cases in which ER-positivity was stable [24]. Here, ESR1 is linked to metastatic neoplasm.